<DOC>
	<DOCNO>NCT00908856</DOCNO>
	<brief_summary>This study examine safety two different cellular therapy treatment stroke .</brief_summary>
	<brief_title>Autologous Cell Therapy After Stroke</brief_title>
	<detailed_description>Stroke remain leading cause death disability . A limited number therapy , intravenous tissue plasminogen activator , approve interrupt stroke early hour symptom onset . Many patient able benefit therapy , however , need exists development new intervention reduce disability stroke . This study early step towards , examine safety two cell type , mononuclear cell marrow stromal cell . In case , cell autologous , specifically derive subject 's bone marrow .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Ischemic stroke supratentorial location &lt; 72 hour old stroke onset bone marrow aspiration No major prestroke disability NIH stroke scale score 724 Able undergo bedside bone marrow aspiration Age 1885 year , inclusive Reasonable likelihood receive standard physical , occupational speech rehabilitation therapy No major active hematological , immunological , oncological diagnosis Pregnancy Lactating mother At least 24 hour time thrombolytic therapy time bone marrow aspiration Allergy penicillin fetal bovine serum Active , major coexistent neurological psychiatric disease Infection HIV , hepatitis B C , syphilis Any diagnosis make survival 90 day poststroke unlikely Participation experimental therapeutic clinical trial prior three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stroke cell therapy repair autologous</keyword>
</DOC>